Pfizer, a pharmaceutical multinational based in New York City, has agreed to a licensing agreement that would allow Pfizer’s experimental covid-19 medicine to be produced more widely throughout the world. It’s an agreement that suggests around half of the globe’s population could gain access to the treatment, even as Pfizer dismisses demands for poorer nations’
The drug, paxlovid, a pill combination called paxlovid that was developed by Pfizer and is now being marketed by Teva Pharmaceuticals, reduced the likelihood of hospitalization or death from covid-19 by 89 percent when taken within three days of the start of symptoms. It has not been authorized in the United States yet.